vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPROCORE TECHNOLOGIES, INC.（PCOR）の財務データ比較。上の社名をクリックして会社を切り替えられます
PROCORE TECHNOLOGIES, INC.の直近四半期売上が大きい（$349.1M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.9倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -10.8%、差は24.1%）。PROCORE TECHNOLOGIES, INC.の前年同期比売上増加率が高い（15.6% vs -1.8%）。PROCORE TECHNOLOGIES, INC.の直近四半期フリーキャッシュフローが多い（$109.2M vs $24.6M）。過去8四半期でPROCORE TECHNOLOGIES, INC.の売上複合成長率が高い（13.8% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Procore Technologiesは2002年に設立された米国の建設管理SaaS企業で、本社はカリフォルニア州カーピンテリアにあります。同社のグローバルプラットフォームは建設業関係者をつなぎ、簡素化されたワークフローの構築、タスク追跡、プロジェクトフロー管理、スケジュール調整などの機能を統合的に提供しています。
AMPH vs PCOR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $349.1M |
| 純利益 | $24.4M | $-37.6M |
| 粗利率 | 46.8% | 80.1% |
| 営業利益率 | 19.4% | -12.3% |
| 純利益率 | 13.3% | -10.8% |
| 売上前年比 | -1.8% | 15.6% |
| 純利益前年比 | -35.7% | 39.6% |
| EPS（希薄化後） | $0.51 | $-0.25 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $349.1M | ||
| Q3 25 | $191.8M | $338.9M | ||
| Q2 25 | $174.4M | $323.9M | ||
| Q1 25 | $170.5M | $310.6M | ||
| Q4 24 | $186.5M | $302.0M | ||
| Q3 24 | $191.2M | $295.9M | ||
| Q2 24 | $182.4M | $284.3M | ||
| Q1 24 | $171.8M | $269.4M |
| Q4 25 | $24.4M | $-37.6M | ||
| Q3 25 | $17.4M | $-9.1M | ||
| Q2 25 | $31.0M | $-21.1M | ||
| Q1 25 | $25.3M | $-33.0M | ||
| Q4 24 | $38.0M | $-62.3M | ||
| Q3 24 | $40.4M | $-26.4M | ||
| Q2 24 | $37.9M | $-6.3M | ||
| Q1 24 | $43.2M | $-11.0M |
| Q4 25 | 46.8% | 80.1% | ||
| Q3 25 | 51.4% | 79.7% | ||
| Q2 25 | 49.6% | 79.1% | ||
| Q1 25 | 50.0% | 79.1% | ||
| Q4 24 | 46.5% | 81.2% | ||
| Q3 24 | 53.3% | 81.4% | ||
| Q2 24 | 52.2% | 83.1% | ||
| Q1 24 | 52.4% | 83.0% |
| Q4 25 | 19.4% | -12.3% | ||
| Q3 25 | 13.2% | -4.4% | ||
| Q2 25 | 24.2% | -9.3% | ||
| Q1 25 | 21.9% | -11.7% | ||
| Q4 24 | 24.2% | -21.9% | ||
| Q3 24 | 29.8% | -12.3% | ||
| Q2 24 | 30.3% | -5.2% | ||
| Q1 24 | 27.9% | -7.0% |
| Q4 25 | 13.3% | -10.8% | ||
| Q3 25 | 9.0% | -2.7% | ||
| Q2 25 | 17.8% | -6.5% | ||
| Q1 25 | 14.8% | -10.6% | ||
| Q4 24 | 20.4% | -20.6% | ||
| Q3 24 | 21.1% | -8.9% | ||
| Q2 24 | 20.8% | -2.2% | ||
| Q1 24 | 25.1% | -4.1% |
| Q4 25 | $0.51 | $-0.25 | ||
| Q3 25 | $0.37 | $-0.06 | ||
| Q2 25 | $0.64 | $-0.14 | ||
| Q1 25 | $0.51 | $-0.22 | ||
| Q4 24 | $0.74 | $-0.42 | ||
| Q3 24 | $0.78 | $-0.18 | ||
| Q2 24 | $0.73 | $-0.04 | ||
| Q1 24 | $0.81 | $-0.08 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $768.5M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $1.3B |
| 総資産 | $1.6B | $2.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $768.5M | ||
| Q3 25 | $276.2M | $684.0M | ||
| Q2 25 | $231.8M | $620.9M | ||
| Q1 25 | $236.9M | $566.7M | ||
| Q4 24 | $221.6M | $775.4M | ||
| Q3 24 | $250.5M | $756.9M | ||
| Q2 24 | $217.8M | $735.4M | ||
| Q1 24 | $289.6M | $744.6M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.3B | ||
| Q3 25 | $776.7M | $1.2B | ||
| Q2 25 | $757.5M | $1.2B | ||
| Q1 25 | $751.3M | $1.2B | ||
| Q4 24 | $732.3M | $1.3B | ||
| Q3 24 | $727.7M | $1.3B | ||
| Q2 24 | $713.3M | $1.3B | ||
| Q1 24 | $672.4M | $1.2B |
| Q4 25 | $1.6B | $2.2B | ||
| Q3 25 | $1.7B | $2.1B | ||
| Q2 25 | $1.6B | $2.0B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.6B | $1.9B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $114.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $109.2M |
| FCFマージンFCF / 売上 | 13.4% | 31.3% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.6% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $282.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $114.9M | ||
| Q3 25 | $52.6M | $88.5M | ||
| Q2 25 | $35.6M | $30.8M | ||
| Q1 25 | $35.1M | $66.0M | ||
| Q4 24 | $29.0M | $29.1M | ||
| Q3 24 | $60.0M | $39.3M | ||
| Q2 24 | $69.1M | $58.7M | ||
| Q1 24 | $55.3M | $69.1M |
| Q4 25 | $24.6M | $109.2M | ||
| Q3 25 | $47.2M | $83.1M | ||
| Q2 25 | $25.0M | $27.9M | ||
| Q1 25 | $24.4M | $62.0M | ||
| Q4 24 | $16.6M | $17.4M | ||
| Q3 24 | $46.2M | $35.7M | ||
| Q2 24 | $63.1M | $56.8M | ||
| Q1 24 | $46.5M | $67.1M |
| Q4 25 | 13.4% | 31.3% | ||
| Q3 25 | 24.6% | 24.5% | ||
| Q2 25 | 14.3% | 8.6% | ||
| Q1 25 | 14.3% | 20.0% | ||
| Q4 24 | 8.9% | 5.8% | ||
| Q3 24 | 24.1% | 12.1% | ||
| Q2 24 | 34.6% | 20.0% | ||
| Q1 24 | 27.1% | 24.9% |
| Q4 25 | 4.5% | 1.6% | ||
| Q3 25 | 2.8% | 1.6% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 6.3% | 1.3% | ||
| Q4 24 | 6.7% | 3.9% | ||
| Q3 24 | 7.2% | 1.2% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 5.1% | 0.8% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
